NASDAQ:KRSA
Korsana Biosciences, Inc.
Korsana Biosciences, Inc.'s revenue grew 3.7% in fiscal 2025 to $2.1M while operating margin fell to −239.8%. The diluted share count rose 26.3%.Summary generated from Korsana Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.1M
Revenue growth+3.7%
Revenue, 5-yr CAGR−2.0%
Gross marginn/a
Operating margin−239.8%
Net margin−170.1%
ROICn/a
Return on equity−39.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+26.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 | 0 | 0 | 2 | 2 |
| Operating income | −55 | −19 | −13 | −4 | −5 |
| Net income | −52 | −44 | −5 | −3 | −4 |
| Free cash flow | −37 | −41 | n/a | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Sep 11, 2026 - 4Insider transaction report
Sep 10, 2026 - 4Insider transaction report
Sep 10, 2026 - 8-KResults of a shareholder vote
Aug 27, 2026 - 8-KOther events
Aug 25, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 10-K/AAmended annual report for the fiscal year ended Dec 31, 2025
Apr 30, 2026